Thursday June 9

08:30-08:45

Welcome
I.Šebesta

Session 1: Purine and pyrimidine analogues
Chairs: G.J.Peters, J.Balzarini

08:45-09:15 Invited lecture

Mechanistic aspects of acyclic nucleoside phosphonates (ANP) activity in biological systems
A.Holý (Czech Republic)

09:15-09:30

Thymidine phosphorylase is non-competitively inhibited by 5'- O -trityl-inosine (KIN59) and related compounds
J. Balzarini, S. Liekens, E. De Clercq, A.-I. Hernández, E.M. Priego, M.-J. Camarasa, M.-J. Pérez-Pérez (Belgium)

09:30-09:45

Resistance to deoxynucleoside analogs mediated by the drug efflux pumps MRP 4 and 5
A.D. Adema, L. Zuurbier, K. Floor, P. Borst, G.J. Peters (The Netherlands)

09:45-10:00

The effect of 9- ß -D-arabinofuranosylguanine on mtDNA
S. Curbo, M. Johansson, I. Khvorostov, N.-G. Larsson, L.D. Lewis, A. Karlsson (Sweden)

10:00-10:15

A novel thymidine kinase in enhanced gap junction mediated suicide gene therapy.
P. Kristoffersen, M. Willer, Z. Khan, T.J. Ekström, P.M. Almqvist, Z. Gojkovic (Denmark)

10:15-10:45 Coffee/tea break

 

Session 2: Thiopurines in therapy
Chairs:.M.A.Becker, R.A.De Abreu

10:45-11:15 Invited lecture

Thiopurine pharmacogenetics-role for therapeutic effects and adverse reaction in childhood ALL and inflammatory bowel disease.
C. Peterson, U. Hindorf, M. Lindqvist, S. Almer (Sweden)

11:15-11:30

Combination therapy in childhood leukaemia: in vitro studies of the cytotoxicity of inhibitors of (thio)purine metabolism and polyamine antimetabolites.
R.A. De Abreu, V.J.M.I. Cuijpers, S.J.G. Hoefs, M. van der Zande, J. Vinck, H. Schotman, B.P. van den Heuvel, A.A.J. Verhofstad, R.G. Schipper (The Netherlands)

11:30-11:45

Pharmacogenetics of azathioprine therapy for inflammatory bowel disease
M. Arenas, A. Ansari, J. Sanderson, A. Marinaki (UK)

11:45-12:00

Pharmacogenetics during initiation of thiopurine treatment in inflammatory bowel disease
M. Lindqvist, U. Hindorf, S. Almer, P. Söderkvist, M. Ström, H. Hjortswang, C. Peterson (Sweden)

12:00-12:15

Uptake and metabolism of thiopurines in human red blood cells (RBC) in vitro
H. Iven, S. Gutsche, A. Kotalczyk (Germany)

12:15-12:30

Thiopurine S -methyltransferase activity (TPMT) is modulated by median age of red blood cells
S. Gutsche, A. Kotalczyk, H. Iven (Germany)

12:30-14:00 Lunch

14:00-15:30 Posters viewing; coffee/tea

 

Session 3: 3A - Role of Adenosine; 3B -Various topics
Chairs:O.Sperling, A.Griesmacher

15:30-15:45

Extracellular ATP and adenosine: two important counterparts in the vasculature
G.G. Yegutkin, S.S. Samburski, S. Jalkanen (Finland)

15:45-16:00

Extracellular adenosine on tumor surveillance; difference in murine and human natural killer cells
M. Koshiba (Japan)

16:00-16:15

HIF-1 dependent repression of equilibrative nucleoside transporter (ENT) expression promotes extracellular adenosine accumulation during hypoxia
H.K. Eltzschig, P. Abdulla, E. Hoffman, K.E. Hamilton, D. Daniels, C. Schönfeld, M. Duszenko, I.R. Coe, S.P. Colgan (USA, Germany)

16:15-16:30

Apically sorted P2X7 receptors mediate purinergic-induced pore formation both in apical and basolateral domains of the plasma membrane
G.I. Gorodeski (USA)

16:30-16:45

The novel nucleotide 4KNTP, in high concentrations in erythrocytes of renal failure children: a comparison with accumulation of other putative precursors in the plasma
E. Synesiou, H.A. Simmonds, L. Fairbanks, E.A. Carrey (UK)

16:45-17:00

Degradation of pyrimidines: indications for a novel uracil degradation pathway
G. Andersen, S. Polakova, Z. Gojkovic, A. Hofer, J. Piskur (Sweden)

17:00-17:15

Degradation of pyrimidines: transamination of beta-alanine, the end-product of pyrimidine reductive degradation
G. Andersen, D. Dobritzsch, K. Schnackerz, J. Piskur (Sweden)

17:15-17:30

Polymorphisms in folate and pyrimidine metabolism predict clinical response to methotrexate therapy in psoriasis
E. Campalani, M. Arenas, A.M. Marinaki, J.N.W.N. Barker, C.H. Smith (UK)

Friday June 10

Session 4: Role of uric acid, Gout
Chairs: J.G.Puig, I.Šebesta

08:30-09:00 Invited lecture

Uric acid and kidney disease
J.S. Cameron (UK)

09:00-09:30 Invited lecture

The association of uric acid with cardiovascular disease and the metabolic syndrome
T. Nakagawa, R.J. Johnson (USA)

09:30-09:45

A study comparing the safety and efficacy of oral febuxostat and allopurinol in Subjects with Hyperuricemia and Gout
M.A. Becker, H.R. Schumacher, R.L. Wortmann, P.A. MacDonald, W. Palo, N. Joseph-Ridge (USA)

09:45-10:15 Invited lecture

The genetics of hyperuricaemia
A.M. Marinaki, H.A. Simmonds, L.D. Fairbanks (UK)

10:15-10:30

Familial nephropathy associated with hyperuricemia in Spain . Past, present and future
J.G. Puig, C. Prior, R.J. Torres (Spain)

10:30-10:50

Genetic heterogeneity of uromodulin associated kidney diseases
S. Kmoch, M. Kublová, P. Vyleťal, M. Kalbáčová, K. Hodaňová, V. Barešová, B. Stibůrková, J. Sikora, H. Hůlková, J. Majewski, A. Marinaki, A. Simmonds, J.-P. Fryns, G. Venkat-Raman (Czech Republic)

10:50-11:15 Coffee/tea break

Session 5: Enzymes I
Chairs:E.Marinello, W.Makarewicz

11:15-11:45 Invited lecture

Cross-talk of nucleoside metabolism and signalling by nucleotides-implications for the cardiovascular system
R.T. Smolenski, A.H.Y. Yuen, I. Rybakowska, M. Zdunek, T. Borkowski, E.M. Slominska, K. Kaletha, M.H. Yacoub (Poland)

11:45-12:00

Modulation of AMP deaminase aktivity in the ischemic heart and its effect on nucleotide pool and metabolic regulation
T. Borkowski, E.M. Slominska, R.T. Smolenski (Poland)

12:00-12:15

Atorvastatin Enhances Extracellular ATP Breakdown in Valve Interstitial cells:- implications for valve calcification
L. Osman, A Chester, M Amrani, C Ilsley, M H. Yacoub, RT Smolenski

12:15-12:30

Effect of the neuroleptic Chlorpromazine on phospholipid and nucleotide metabolism in human lymphocytes and neuroblastoma cell lines
M. Staub, G. Keszler, R. Sümeg, T. Spasokoukotskaja, L. D. Fairbanks, H. A. Simmonds (Hungary)

12:30-12:45

Crystal structures of human deoxyribonucleotidases
A. Rinaldo-Matthis, K. Wallden, Ch. Rampazzo, B. Ruzzenente, P. Reichard, V. Bianchi, P. Nordlund (Sweden)

12:45-13:00

Thymidylate synthase ThyX - a new therapeutic target
S. Graziani, D. Leduc, S. Skouloubris, H. Myllykallio, U. Liebl (France)

13:00-14:00 Lunch

14:00-15:30 Posters viewing ; coffee/tea

Session 6: Enzymes II
Chairs: T.Zima, B.Munch-Petersen

15:30-15:45 Invited lecture

History and presence of purine research in Prague
S.Štípek,I.Šebesta, T.Zima, S.Kmoch (Czech Republic)

15:45-16:00

Identification of phosphorylation sites on human deoxycytidine kinase after overexpression in eucaryotic cells
C. Smal, D. Vertommen, L. Bertrand, S. Cardoen, M. Rider, A. Ferrant, G. Van den Berghe, E. Van Den Neste, F. Bontemps (Belgium)

16:00-16:15

No direct evidence for the regulation of deoxycytidine kinase activity by reversible phosphorylation
G. Keszler, T. Spasokoukotskaja, M. Sasvári-Székely, S. Eriksson, M. Staub (Hungary)

16:15-16:30

Deoxyribonucleoside kinase evolution - Same reaction catalyzed by two enzyme families.
M.P.B. Sandrini, A.R. Clausen, B. Munch-Petersen, J. Piskur (Denmark, Sweden)

16:30-16:45

Species-specific activation of prodrugs by deoxyribonucleoside kinases.
A.R. Clausen, B. Munch-Petersen, F.M. Aarestrup, L.B. Jensen, S.L. On,, J.Piskur, M.P.B. Sandrini (Sweden)

16:45-17:00

Active site mutants of thymidine kinases from human and Caenorhabditis elegans
T. Skovgaard, M. Thuno, B. Munch-Petersen (Denmark)

17:00-17:15 Coffee/tea break

Session 7: Analytical techniques
Chairs:A.B.P.Van Kuilenburg, D.Perrett

17:15-17:30

Hepatic extraction of gemcitabine, as determined by LC-APCI-MS/MS after intravenous (IV) administration and hepatic artery infusion (HAI): effects on deoxycytidine.
G.J. Peters, R. Honeywell, A.C. Laan, E Strocchi, R. Ruiter, G. Giaccone, C.J. van Groeningen. (The Netherlands)

17:30-17:45

Micro-array analysis of in vivo resistance to Gemcitabine: Increased expression of ribonucleotide reductase subunit M1
K. Smid, A.M. Bergman, P.P. Eijk, V.W.T. Ruiz van Haperen, G. Veerman, I. Hubeek, P. van den Ijssel, B. Ylstra, G.J. Peters (The Netherlands)

17:45-18:00

Liquid chromatographic/mass spectrometric procedure for measurement of NAD catabolites in human and rat plasma and urine.
E.M. Slominska, K. Bury, P. Adamski, M. Lipinski, J. Swierczynski, R.T. Smolenski (Poland)

 

Saturday June 11

Session 8: Inborn errors
Chairs:H.A.Simmonds, M.M.Müller

08:30-09:00 Invited lecture

AICA-ribosiduria: a novel inborn error of purine biosynthesis
M.-F. Vincent, B. Héron, P. Bitoun, T. Timmerman, G. Van den Berghe, S. Marie (Belgium)

09:00-09:15

Hypoxanthine effect on equilibrative and concentrative adenosine transport in human lymphocytes. Implications in the pathogenesis of Lesch-Nyhan syndrome
C. Prior, R.J. Torres, J.G. Puig (Spain)

09:15-09:30

Biochemical study of two HPRT deficient patients with mild neurological syndrome
V.Micheli, G.Jacomelli, M.Bertelli, A.Cossu, L.Peruzzi, L.Peruzzi, B.Cerboni, M.R Corradi, S.Sestini, G.Pompucci (Italy)

09:30-09:45

Study of expression of the adenosinergic receptors and adenosine levels in the brain of knock-out mice for HPRT gene
M. Bertelli, S. Cecchin, V. Micheli, C. Lapucci, G. Jacomelli, H.A. Jinnah, M. Pandolfo (Italy)

09:45-10:00

Towards diagnosing defects in purine de novo synthesis pathway
T. Adam, P. Vyskočilová, E. Hlídková, H. Kuchyňová, L. Opluštilová, K. Adamová, A. Janošťáková, D. Friedecký (Czech Republic)

10:00-10:15

ß -Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities
A.B.P. Van Kuilenburg, R. Meinsma, E. Beke, B. Assmann, A. Ribes, I. Lorente, R. Busch, E. Mayatepek, N.G.G.M. Abeling, A. Van Cruchten, A.E.M. Stroomer, H. Van Lenthe, L. Zoetekouw, W. Kulik, G.F. Hoffmann, T. Voit, R.A. Wevers, F. Rutsch, A.H. Van Gennip (The Netherlands)

10:15-10:45 Coffee/tea break

Session 9: Role of mitochondria
Chairs: V.Micheli, E.A.Carrey

10:45-11:00

Thymidine phosphorylase administration through platelets infusion transiently reduces nucleoside accumulation in MNGIE
M.C. Lara, I. Illa, P. Madoz, L. Massuet, A.L. Andreu, M. Hirano, R. Martí (Spain)

11:00-11:15

Deoxynucleotide pools in MNGIE: an experimental model
G. Pontarin, P. Ferarro, S. Fabris, K. Crovatto, V. Bianchi, P. Reichard (Italy)

11:15-11:30

Origins of mitochondrial deoxyribonucleotides in cycling and resting cells
Ch. Rampazzo, P. Ferraro, K. Crovatto, S. Fabris, B. Ruzzenente, P. Reichard, V. Bianchi (Italy)

11:30-11:45

Is there a link between dNTP pools, mitochondrial function and mutagenesis?
C. Desler, M. Sanderhoff, B. Munch-Petersen, L.J. Rasmussen (Denmark)

11:45-12:00

AICA riboside induces apoptosis in human neuroblastoma cells via the mitochondrial pathway
M. Garcia-Gil, F. Bertini, R. Pesi, V. Voccoli, M. Tozzi, M. Camici (Italy)

12:00-12:15 Last minute breaking-news

Endogenously expressed truncated P2X 7 receptor lacking the C-terminal (P2X 7 -R Tr ) is preferentially upregulated in epithelial cancer cells and fails to mediate ligand-induced pore formation and apoptosis
Ying-Hong Feng, G.Gorodeski (USA)

12:15 Concluding remarks, Poster Prize, Invitation PP'07

13:00-14:00 Lunch